Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous cytoplasmic activated PD-1 CAR-Tcells

A preparation of autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), carrying cytoplasmic activated programmed cell death 1 (PD1; PDCD1; CD279; programmed death-1), with potential antineoplastic activity. Upon intravenous administration, autologous cytoplasmic activated PD-1 CAR-T cells target, bind to, and induce selective toxicity in CD19-expressing tumor cells. The cytoplasmic activated PD1, a negative immunoregulatory human cell surface receptor, normally binds to programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) on tumor cells, causing T-cell inactivation. By preventing PD1/PD-L1 signaling, T-cell exhaustion is abrogated, and T-cell activation is enhanced leading to an increased cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. CD19 is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.
Synonym:autologous CAR19 T cells carrying cytoplasmic activated PD-1
Search NCI's Drug Dictionary